Review

Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy

Gaëtan Jego1,2,*†, François Hermetet1,2,†, François Girodon1,2,3 and Carmen Garrido1,2,4,*‡

1 INSERM, LNC UMR1231, team HSP-Pathies, University of Bourgogne Franche-Comté, F-21000 Dijon, France; francois.hermetet@u-bourgogne.fr (F.H.); francois.girodon@chu-dijon.fr (F.G.)
2 UFR des Sciences de Santé, University of Burgundy and Franche-Comté, F-21000 Dijon, France
3 Haematology laboratory, Dijon University Hospital, F-21000 Dijon, France
4 Centre Georges François Leclerc, 21000 Dijon, France
* Correspondence: cgarrido@u-bourgogne.fr (C.G.); gaetan.jego@u-bourgogne.fr (G.J.);
Tel.: +33-3-8039-3345 (G.J.); Fax: +33-3-8039-3434 (C.G. & G.J.)
† These authors contributed equally to this paper.

Received: 16 October 2019; Accepted: 13 December 2019; Published: 19 December 2019

Abstract: While cells from multicellular organisms are dependent upon exogenous signals for their survival, growth, and proliferation, commitment to a specific cell fate requires the correct folding and maturation of proteins, as well as the degradation of misfolded or aggregated proteins within the cell. This general control of protein quality involves the expression and the activity of molecular chaperones such as heat shock proteins (HSPs). HSPs, through their interaction with the STAT3/STAT5 transcription factor pathway, can be crucial both for the tumorigenic properties of cancer cells (cell proliferation, survival) and for the microenvironmental immune cell compartment (differentiation, activation, cytokine secretion) that contributes to immunosuppression, which, in turn, potentially promotes tumor progression. Understanding the contribution of chaperones such as HSP27, HSP70, HSP90, and HSP110 to the STAT3/5 signaling pathway has raised the possibility of targeting such HSPs to specifically restrain STAT3/5 oncogenic functions. In this review, we present how HSPs control STAT3 and STAT5 activation, and vice versa, how the STAT signaling pathways modulate HSP expression. We also discuss whether targeting HSPs is a valid therapeutic option and which HSP would be the best candidate for such a strategy.

Keywords: heat shock proteins; chaperones; stabilization; targeted therapy

1. Introduction to Heat Shock Proteins/Chaperones

Heat shock proteins (HSPs), also called stress proteins, are highly conserved molecular chaperones induced by a broad variety of exogenous or intracellular stresses, including chemotherapy. Based on their molecular weight, HSPs have been classified into five conserved families: HSP110 (also called HSPH), HSP90 (HSPC), HSP70 (HSPA), HSP60 (HSPD/E), and the small HSPs (HSPB). The expression of HSPs is mostly regulated by heat shock factor 1 (HSF1), which is able to translocate from the cytoplasm to the nucleus following stress to bind to a short, highly conserved DNA sequence known as a heat shock element (HSE) [1]. As cytoprotective proteins, HSPs participate in the correct folding, activity, transport, and stability of proteins [2], which are essential processes for cell survival. In physiological conditions, these proteins support neosynthesized proteins, favoring post-translational modification processes and protein folding. Otherwise, the functions attributed to them include the subcellular transport of their “client” proteins, or participation in certain signaling pathways. In response to stress, many partially denatured proteins accumulate and cluster together forming protein aggregates via the exposure of their hydrophobic residues. Some HSP proteins are then able...
to bind to these partially denatured proteins, thus preventing protein aggregation and favoring their correct folding. However, HSPs can also promote the elimination of these proteins by orienting them towards different degradation pathways, notably the ubiquitin–proteasome system, when correct folding is no longer possible. It has also been reported that HSP proteins are able to inhibit the intrinsic apoptotic (inhibition of apoptosome formation) and extrinsic (inhibition of signal transduction of death receptors) processes [3,4]. Interestingly, HSPs can also be secreted and act extracellularly via membrane receptors or within extracellular vesicles as a damage-associated molecular pattern and exhibit immune-cell dysregulation properties.

2. HSP Chaperones and Cancer

As cancer cells accumulate mutations and generate physiologically stressful conditions, they require a constitutively high level of HSPs for their survival and maintenance. In 2011, in order to simplify the complexity of this disease, researchers suggested that tumor development was organized around six essential alterations [5]. These major modifications include (i) self-sufficiency in growth signals; (ii) insensitivity to growth inhibition; (iii) tissue invasion and capacity to develop metastases; (iv) unlimited replication potential; (v) de novo angiogenesis; and (vi) inhibition of programmed cell death. Although the appearance of these changes is mainly linked to instability genomics, many studies have demonstrated the involvement of HSPs in these processes, indicating that these molecular chaperones have an oncogenic role. Comprehensive discussion about the oncogene-like functions of these different molecular chaperones and their participation in the progression of resistance to cancer treatment can be found in excellent recent reviews elsewhere [6,7]. Given the role of HSPs in cancer biology, these chaperones have also been suggested as potential therapeutic targets [3,8]. A number of these proteins have been correlated to cancer aggressiveness and/or cancer resistance to radiotherapy and adjuvant chemotherapy [9].

Targeting HSPs has emerged as a promising sensitization strategy in cancer therapy since HSPs have oncogene-like functions and mediate “non-oncogene addiction” of stressed tumor cells that must adapt to a hostile microenvironment. Except for one inhibitor of HSP27 (an antisense oligonucleotide in phase I/II) [10], all the HSP inhibitors used in clinical trials target HSP90 [11,12]. In this review, we mainly focused on the chaperones HSP90, HSP70, HSP110, and HSP27 and their regulation of protein misfolding and signaling in TYK2-STAT3/5 core cancer pathways, as well as the possibility of targeting such HSPs to specifically restrain STAT3/5 oncogenic functions. We also discuss the machinery behind the chaperones, which is becoming a major therapeutic target in cancer, and the emergence of promising HSP inhibitor-based drugs, which are currently being clinically tested or developed for cancer treatment (Table 1).

| Inhibitor | Study Type | Cancer Model | Ref. |
|-----------|------------|--------------|-----|
| Apatosensen (OGX-427) | in vitro/preclinical | Prostate, Ovary | [13,14] |
| 2nd generation 2′-methoxyethyl-modified ASOs | clinical (phase I) | CRPC, Breast, Ovary, Lung, Bladder | [10] |
| | in vitro/preclinical | Pancreatic, NSCLC | [15,16] |
| | clinical (phase II) | stage IV non-squamous NSCLC | [17] |
| 3-arylethynyltriazolyl ribonucleoside ASOs | in vitro | Pancreatic | [18] |
| ASOs-Hsp27 | in vitro | Lymphoma | [19] |
| RP101 (Brivudine) | in vitro/preclinical/clinical | Pancreatic | [20] |
| Inhibitor Study Type Cancer Model Ref. |
|--------------------------------------|
| **Target: HSP70**                     |
| Pifithrin-µ (PFTµ, PES) Drug-like small molecule in vitro AML, ALL, primary AML blasts [21,22] |
| VER-155008 ATP-derivative inhibitor in vitro Breast, Colon, Prostatic, Myeloma [23–25] |
| A17/A8 Peptide aptamer in vitro/preclinical Cervix (HeLa cells), Melanoma [26] |
| ADD70 Peptide aptamer in vitro/preclinical Rat colon carcinoma, Mouse melanoma [27] |
| cmHsp70.1 Antibody preclinical Colorectal [28] |
| Hsp70-peptide targeted NK based adoptive immunotherapy A specific amino acid sequence (TKD) of Hsp70 clinical (phase I/II) NSCLC (and colon cancer) patients with ex vivo Hsp70 peptide activated, autologous NK [29] |
| **Target: HSP90**                     |
| Radicicol Radicicol in vitro CML, [30] |
| 17-AAG; 17-DMAG Derivative of the antibiotic geldanamycin in vitro/preclinical Breast, Brain, Medulloblastoma [31–33] |
| 17-DMAG in vitro Chronic Lymphocytic Leukemia [34] |
| IPI-504 (retaspimycin) Water-soluble derivative of 17-AAG in vitro/preclinical Breast, Pancreatic, Metastatic gastrointestinal Stromal tumor [35–39] |
| IPI-504, AUY922 Ganetespib, Onalespib - phase I–III trials NSCLC Breast, Ovary, Colon [41] |
| Novobiocin Aminocoumarin antibiotic, produced by the actinomycete Streptomyces nivens in vitro/preclinical Leukemia, Prostate [42–44] |
| Panaxynol Natural pesticide and fatty alcohol in vitro/preclinical Lung [45] |
| Ganetespib (STA-9090) Resorcinol derivative preclinical trial Thyroid [46] |
| BIB021 (CNF2024) Orally available, fully synthetic purine scaffold, in vitro/preclinical Blood malignancies, Solid tumors [48] |
| PU-H71 Non-ansamycin, purine scaffold HSP90 inhibitor in vivo mouse models of the MPN PV and ET MPN [49] |
| Inhibitor                      | Study Type          | Cancer Model                                                   | Ref.                |
|-------------------------------|---------------------|----------------------------------------------------------------|---------------------|
| NVP_AUY922 (AUY922)           | in vitro/preclinical| Gastric, Small cell lung, Thyroid carcinoma                   | [51–55]             |
|                               | in vitro            | 32D mouse hematopoietic cells expressing wild-type BCR-ABL (b3a2, 32Dp210) and mutant BCR-ABL imatinib-resistant cell lines | [56]                |
|                               | in vitro/preclinical| Drug-resistant chronic myelogenous leukemia                    | [57]                |
|                               | clinical trial (II) | Myeloproliferative neoplasms                                   | [58]                |
|                               | clinical trial (III)| EGFR—mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors | [59]                |
| NVP_AUY922 (AUY922) HSP990, PU-H71 | in vitro/in vivo | Leukemia                                                       | [60]                |
| Onalespib (AT13387)           | in vitro            | Transformed kidney cells, primary lung adenocarcinoma          | [61]                |
|                               | in vitro/in vivo    | Melanoma                                                       | [62]                |
|                               | in vitro/preclinical| NSCLC                                                          | [63]                |
|                               | in vitro/preclinical| NSCLC                                                          | [64]                |
| XL888                         | clinical trial (I)  | Melanoma                                                       | [65]                |
| SNX2112 SNX3422               | in vitro/preclinical| Head and neck squamous cell carcinoma                          | [66]                |
|                               |                     | NSCLC                                                          | [67]                |
| CUDC-305, Ganetepib, CH5164840, WK88-1 17-DMAG | preclinical | NSCLC                                                          | [68–71]             |
| Foldamers 33 and 52           | Protein–protein interaction inhibitors, based on pyridyl scaffolds mimicking α-helix | in vitro/in vivo | Colorectal [72] |

CRPC: castration-resistant prostate; ASOs: antisense oligonucleotides; siRNA: small interference RNA; HSF1: heat shock factor 1; PES: 2-phenylethynylsulfonamide; NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; TMZ: temozolomide; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; SBD: substrate-binding domain; NK: natural killer cells; CML: chronic myelogenous leukemia; MPN: myeloproliferative neoplasm; PV: polycythemia vera; ET: essential thrombocytosis.
3. HSP90

3.1. HSP90 Structure and Functions

HSP90 (also known as HSPC) is one of the most abundant chaperones in eukaryotic cells in the absence of stress. HSP90 is critical for the operation of cellular machinery under physiological conditions through interactions with so-called “client” proteins. This is only achieved through the formation of a multimeric protein complex of cochaperones that binds to all three domains of HSP90. Hundreds of client proteins for HSP90 have been identified so far [73]. Many of these proteins are involved in essential cellular functions that promote cell growth, proliferation, cell survival, and immune responses. Most of these processes are also involved in cancer development. Three main groups of “client proteins” can be described for HSP90: first, the group of kinases represents the main group because HSP90 interacts with 60% of them [74]; second, the group of multiprotein complexes for which HSP90 promotes assembly [75]; and third, the group of ligands that HSP90 stabilizes with their receptors. It is difficult to identify new client proteins because HSP90 does not bind particular sequences. In contrast, the interaction seems to be based on the overall structural instability of the client proteins [74,76]. Among the client proteins, here we focus on the kinases and receptor tyrosine kinases involved in the STAT3/5 signaling pathway.

3.2. HSP90 and Nonfusion Protein Kinases

3.2.1. Jak Kinases

The mammalian family of Janus kinases (JAKs) is composed of 4 members: JAK1, JAK2, JAK3, and Tyrosine kinase 2 (Tyk2). This family is the main activator of STAT proteins. JAK regulation by HSP90 was discovered by studying the effect of HSP90 inhibitors on the type I and II Interferon (IFN) signaling. In several cell lines, this treatment suppressed the expression of multiple IFN-γ-induced genes and decreased IFN-γ-induced STAT1 phosphorylation on Tyr-701, required for dimerization, and on Ser-727, required for transcription factor activation. As JAK1/2 were known to be the protein kinases responsible for STAT1 phosphorylation, Shang et al. investigated the effect of HSP90 inhibitors on JAK1/2. They showed that HSP90 inhibition led to the proteasome-mediated degradation of JAK1/2. Further they showed that JAK1 interacted with HSP90 (and the CDC37 cochaperone [77]), and that both interactions were destabilized by HSP90 inhibitors [78]. As overactivation or constitutive JAK1/2 signaling promotes cell proliferation and survival in a variety of solid tumors and leukemia [79,80], this discovery paved the way for the identification of the critical role of HSP90 in the aberrant JAK/STAT signaling pathway. In particular, an activating point mutation in JAK2 (JAK2V617F) was described as being highly frequent in chronic myeloproliferative neoplasms (MPN) that promote disease progression [81–84].

Despite this activating mutation, HSP90 inhibition in cell lines homozygous for JAK2V617F reduced total and phospho-JAK2, and subsequently cell viability [85]. In vivo experiments in a mouse model of MPN confirmed the efficacy of HSP90 targeting because treatment with the HSP90 inhibitor PU-H71 resulted in significant reductions in disease parameters and better chances of survival [49]. Furthermore, combined treatment that included HSP90 inhibitors and JAK2 inhibitors induced a greater depletion of the signaling proteins than a single inhibitor alone, and synergistically induced apoptosis in human primary CD34(+) MPN cells harboring JAK2V617F [50]. Therefore, HSP90 interaction with JAK2 is not altered by activated mutations, but instead could be used as a therapeutic target. This point is of great value, as mutations within the JAK2 kinase domain that confer resistance across a panel of JAK inhibitors have been described (G935R, Y931C, and E864K). Fortunately, genetic resistance to JAK2 enzymatic inhibitors can be overcome by HSP90 inhibitors, which still promote the degradation of both wild-type and mutant JAK2 [60]. Recently, results from a phase II clinical trial with the HSP90 inhibitor AU922 (Novartis, transferred to Vernalis) have been published and have demonstrated a clinical response in five out of seven patients with MPN [58]. This response correlated with a reduction in overall levels of JAK2, pYSTAT3, and pYSTAT5. Unfortunately, most patients experienced severe
adverse effects due to the toxicity of the inhibitor, a phenomenon that has already been observed with other HSP90 inhibitors.

3.2.2. Src Kinases

The members of the Src family of nonreceptor tyrosine kinases (Src, Fyn, Yes, Blk, Yrk, Rak, Fgr, Hck, Lck, Srm, and Lyn) are implicated in numerous important functions in eukaryotic cells. They control proliferation, survival, and differentiation, therefore playing a critical role in many cancer types [86]. Src members can activate STAT3 directly and synergize with JAK family tyrosine kinase action [87]. Among the family members, c-Src has been linked to cancer development [88]. The viral homolog of c-Src kinase, v-Src (from the Rous sarcoma virus), has a constitutive kinase activity and was the first discovered oncogene [89,90]. Both homologs bind to the HSP90/CDC37 complex but with striking differences. HSP90, which binds weakly and transiently to c-Src, binds strongly to v-Src, which appears to be its strongest client protein [91–93]. Accordingly, v-Src kinase activity depends strongly on HSP90 [74,94]. Recently, Boczek et al. provided more insight by determining the influence of HSP90 isoforms α and β on purified c-Src and v-Src activity. They have shown that HSP90 does not affect c-Src activity in vitro, whereas v-Src activity was increased two-fold when human HSP90β (but not HSP90α) was added to the experimental setting. HSP90β also stabilized v-Src at high temperatures when it would be inactive otherwise. Until recently, the mechanism behind this striking difference was unknown [76,95]. To solve this issue, Bolcek et al. generated an Src mutant that mimics the oncogenic v-Src kinase activity (c-src3MΔC). This mutant exhibited a more extended activation loop (A-loop) (usually present in an open form during wild-type Src active state to allow substrate binding). The A-loop from c-Src3MΔC is also less stable in comparison with the wild-type Src. Consequently, the c-Src3MΔC is conformationally uncontrolled, which enhances its interaction with HSP90 and suggests this could be a more general mechanism for the interaction between HSP90 and oncogenic kinases than the presence of a general client sequence motif. Indeed, HSP90 potentially interacts more strongly with structurally extended kinases, a frequent state observed upon activating mutations. Interestingly, a very similar mechanism needed to aid the initial folding of immature kinases such as c-Src, which is furtive is this case, governs the binding of HSP90 to conformationally unstable but mature kinases like v-Src. In this context, CDC37 appears to bind to parts of the unfolded kinase first (which might be considered as an independent kinase binding unit), partly unfolding it further before HSP90 clamps around the CDC37/kinase complex [96]. Other Src family members, like Lck Y505F and HCK 499F, are probably stabilized by the same mechanism [97,98].

3.2.3. ACK1

Another nonreceptor tyrosine kinase, activated CDC42-associated kinase-1 (ACK1), catalyzes the phosphorylation of STAT1, STAT3, and STAT5. HSP90 interacts with ACK1 [99] and is necessary for the phosphorylation of STAT1 in transformed kidney cells and STAT3 in primary lung adenocarcinoma by ACK1 [61].

3.2.4. BRAF

The activated serine/threonine kinase BRAF mutant is a main driver of melanoma growth and progression [100] and is a HSP90 client protein [74,101]. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors [62]. A recent phase I dose escalation clinical trial in melanoma has shown that another HSP90 inhibitor (XL888) in combination with a specific anti BRAF inhibitor (vemurafenib) has clinical activity in patients with advanced BRAF V600-mutant melanoma, with a tolerable side effect profile [65].

3.3. HSP90 and Fusion Protein Kinases

3.3.1. BCR-ABL

Chronic myeloid leukemia (CML) is driven by the BCR-ABL fusion oncoprotein [102], which is involved, among other pathways, in the transcriptional regulation of STAT3 [103,104] and
STAT5 [105,106]. In this context, the BCR-ABL/STAT3/STAT5 signaling pathway is mainly involved in tumor-initiating stem cell maintenance [107]. BCR-ABL is a HSP90 client protein that is destabilized by HSP90 inhibition, which leads to cell death [56]. In CML cells, BCR-ABL forms a high molecular weight network with JAK2, STAT3, and AKT. This network pushes disease progression, but could also be its Achilles’ heel. Indeed, HSP90 directly binds to this signaling network, and its inhibition breaks the whole network apart [56]. As for other targeted therapies, resistance to BCR-ABL tyrosine kinase inhibitors can develop during the course of the treatment because of acquired BCR-ABL mutations. Hopefully, combination therapies involving HSP90 inhibitors and anti-JAK2 may overcome this resistance [57].

We are still unsure of how this mechanism of action can be extended to the interaction with other oncogenic mature kinases, but an important process for protein stabilization by HSP90 and CDC37 has been uncovered.

3.3.2. EML4-ALK

The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene is an oncogenic driver in about 5% of patients with non-small cell lung cancer (NSCLC). It is also an HSP90 client protein (one of the most sensitive), which is very rapidly degraded upon exposure to HSP90 inhibitors [40]. These results prompted the initiation of numerous clinical trials reviewed elsewhere [41,108]. Yet despite encouraging results, clinical response was weak, and so the development of HSP90 inhibitors was halted for NSCLC.

3.4. HSP90 and ErbB Family of Receptor Tyrosine Kinase (RTK)

STAT3 and STAT5 are also known to be phosphorylated by several receptor tyrosine kinases (RTK), such as the ErbB family, IGF-1R, or FGFR [109], most of which are HSP90 client proteins. Interestingly, they are also activated or captured for signal transduction by those RTK without phosphorylation [110]. Given their membrane localization, these RTK must go through a complex process of folding, maturation, and membrane insertion that requires significant chaperone cooperation. This is particularly true for mutated RTK, which is frequently observed in cancers. For instance, ErbB2 stability and maturation is regulated by its binding to HSP90 through its cytoplasmic tail [111] and is ATP dependent [112].

Accordingly, HSP90 inhibition leads to RTK destabilization and absence of STAT3 activation in different models of cancer [47,66,67]. Many drugs have been developed to inhibit mutated or rearranged RTK, but despite early success, most patients develop resistance and eventually relapse [113]. The strong HSP90/EGFR interaction has then been used to propose an alternative therapeutic strategy combining an HSP90 inhibitor with an EGFR inhibitor. Interestingly, this combination (with the EGFR inhibitor erlotinib) resulted in prolonged animal survival in nonmutated and erlotinib-resistant models [67,68,70,71,114,115].

3.5. STAT3/5 and HSP90

The STAT3/5 signaling pathway is also regulated downstream from the tyrosine kinases and RTK. Indeed, HSP90 is found within the cytosol, directly bound to dimers of STAT3 or STAT5 via its N-terminal regions [116]. However, in contrast to its role in TK or RTK folding and stabilization, HSP90 is not required for STAT3/5 maturation or total protein levels. They are therefore nonclassical HSP90 client proteins. The chaperone would rather change STAT conformation to ease the phosphorylation process and/or, once phosphorylated, maintain this active state for a prolonged period of time. Moulick et al. have suggested this pattern in chronic myeloid leukemia [69]. They showed that HSP90 directly binds to active pYSTAT5 (Tyr694), but not to inactive STAT5, and that pYSTAT5 acquires a conformation that is more susceptible to trypsin cleavage in the presence of HSP90. HSP90/STAT3 also protects pYSTAT3 from dephosphorylation by the phosphatase SHP-1 in gastric cancer cells. Luteolin (3,4,5,7-tetrahydroxyflavone), a natural flavonoid present in fruits and vegetables, inhibits
STAT3 activation by disrupting the association of HSP90 to STAT3, which allows it to interact with SHP-1 [117].

In order to function as a transcription factor, STAT3/5 needs to translocate into the nucleus and form a stable interaction with DNA. In this context, as suggested by Longshaw et al., HSP90 appears to play a specific role in association with the cochaperone HOP [118]. They have shown that the depletion of HOP decreased the nuclear localization of STAT3. Although it is not yet clear how HSP90 promotes STAT3/5 nuclear shuttling, it may involve the capacity of HSP90 to form molecular complexes with specific carriers, like importins alpha [119], that can transport STAT3 to the nucleus. This scheme would mimic what has been described for other molecular complexes implicating HSP90, such as the glucocorticoid receptor [120] or PKCZeta [121]. After entering the nucleus, HSP90 seems to promote STAT3/5 transcriptional activity as STAT3/5 interaction with promoters of target genes is enhanced by the presence of HSP90. Indeed, the STAT3/5 complexes and HSP90 have been shown to colocalize in MYC and in CCND2 promoters [69]. Furthermore, nuclear hormone receptors form multiprotein complexes with STAT3 and STAT5 [122,123], which together with HSPs could contribute to chromatin landscaping [124].

In conclusion, HSP90 appears to be a key chaperone for the STAT3/5 pathway. It operates at all levels of message transmission, from interaction with RTK in the cytoplasmic membrane, to the interaction with multiple kinases in the cytosol, and to favoring active STAT3/5 localization and binding of target genes the nucleus (Figure 1). This role is also central in the pathological overactivation of STAT signaling where HSP90 favors oncogenic proteins (Figure 1), promoting the development of several inhibitors for cancer treatment (Table 1, Figure 2). However so far, most clinical trials have yielded mixed results and frequent side effects that precluded the broad utilization of these treatments.

Figure 1. Localization and described functions of HSP90 within the STAT3 and STAT5 signaling pathways. HSP90 promotes those pathways through direct interaction with STAT3 or STAT5 dimers and favors their phosphorylation, nuclear localization, and promoter binding, but HSP90 also limits dephosphorylation and proteasomal degradation. Upstream of STAT3/STAT5 activation, HSP90 stabilizes several kinases, like JAK2, JAK2<sup>V617F</sup>, c-Src, v-Src, ACK1, BCR-ABL, EML4-ALK, Lck<sup>Y505F</sup>, and HCK<sup>499F</sup>, and several receptor tyrosine kinases, such as the ErbB family.
4. HSP27

4.1. HSP27 Structure

HSP27 (27 kDa), also known as HSPB1, belongs to the small HSP family. In contrast to other HSPs, it is an ATP-independent chaperone [125]. HSP27 shows a highly dynamic process of oligomerization that transforms proteins from dimers to large oligomers, which can culminate at 1000 kDa. This state of oligomerization dictates the affinity of HSP27 towards the proteins to be chaperoned, given that the multimer form is the most binding-competent state [126].

Four phosphorylation sites (S15, S78, S82 and T143) in the N-terminal domain regulate the assembly of oligomers [127]. Phosphorylation promotes the formation of small oligomers, while dephosphorylation promotes the formation of large oligomers [128]. Stressors such as anticancer agents, hydrogen peroxide, mitogens, inflammatory cytokines (TNF-α, IL-1β, etc.), and kinases (p38 MAPK, p70RSK, PKB, PKC, PKD and PKG) can promote HSP27 phosphorylation [129]. However, we have also shown that oligomerization can occur independently of phosphorylation through cell–cell contact, as observed in confluent cultures in vitro or solid tumors in vivo [130].
4.2. HSP27 Functions

HSP27 chaperone functions have been less described than higher molecular weight HSPs like HSP70 and HSP90. However, HSP27’s main function as a chaperone is to stabilize denatured or aggregated proteins to bring them to a soluble and stable form [131,132].

HSP27 plays an important role and has been associated with poor prognosis in many cancers (for a recent review, see [127]). For instance, Rocchi et al. described the promotion of the STAT3 signaling pathway in prostate tumors [133]. They showed that HSP27 directly interacts with STAT3 and that total STAT3 levels correlated directly with HSP27 levels. Furthermore, the cytoprotective effect of HSP27 was attenuated by STAT3-reduced expression, underlying the importance of this pathway in prostate cancer [133]. HSP27 is also involved in the process of prostate cancer metastasis through the promotion of IL-6-mediated epithelial-to-mesenchymal transition (EMT), because reduced HSP27 expression decreases cell migration and invasion [134]. In the absence of HSP27, IL-6-induced phosphorylation of STAT3 is reduced, but not total STAT3 content. This inhibition leads naturally to reduced STAT3 nuclear localization and binding to the TWIST gene, which codes for a key EMT transcription factor.

Beside cancer development, HSP27 regulation of STAT3 has recently been implicated in placental implantation. HSP27 is indeed expressed during placenta formation and in the first two trimesters of pregnancy [135,136]. In particular, HSP27 is highly expressed during the differentiation of cytotrophoblast cells and extravillous trophoblast cells, and its silencing was found to significantly reduce total STAT3. Interestingly, the phosphorylation state of STAT3 was not altered in the absence of HSP27 in placental explants, suggesting a role in protein protection from proteasomal degradation [137]. This could be explained by the fact that STAT3 and STAT5 have a relatively low thermodynamic stability as isolated proteins and are thus more prone to aggregation, which would be limited by HSP27 [124]. Given the importance of STAT3 in embryonic development (STAT3 knock-out mice have a lethal embryonic phenotype) [138], this finding revealed the critical role of HSP27 in this process.

There has been little study of the state of HSP27 phosphorylation, and consequently the state of oligomerization, required for STAT3/5 binding, despite the fact that therapeutic targeting of specific kinases would logically impact HSP27 functions. We only know, from one study of prostate cancer, that IL-6 stimulation leads to HSP27 phosphorylation and correlates with the EMT, suggesting the phosphorylated form is required for STAT3 activation [134]. Other STAT family members are HSP27 client proteins, like STAT2 (a STAT family member involved in viral or interferon responses), which was also shown to be degraded upon HSP27 knockdown in Hela cells [139]. However, this process was reversed by proteasome inhibition. However, STAT3 and 5 were not or were only weakly reduced in this particular tumor cell line. Again, the discrepancy between tumoral contexts or cell lines could come from differences in HSP27 phosphorylation or oligomerization status.

As stated previously, HSP27/STAT3 interaction occurs also in nontumoral contexts. In normal liver cells under a high fat diet, the phosphorylated form of HSP27 stimulates autophagy and lipid droplet clearance through interaction with STAT3. In this particular situation, no STAT3 activation by HSP27 is described, but rather the disruption of STAT3/PKR complexes, facilitating PKR and eIF2α mediated autophagy [140]. These data suggest that dimers and multiprotein complexes can be displaced by the action of phospho-HSP27 on different binding partners, including STAT3, and this can also mediate critical cellular physiological processes.

Upstream from STAT3/5 activation, JAK2 plays a major role that can be modulated by HSP27 [141]. In the specific context of thrombopoietin- and JAK2V617F-induced myelofibrosis (a chronic degenerative disorder of the hematopoietic system associated with the aberrant activation of the JAK/STAT pathway) [142], our team has recently shown that HSP27 interacts directly with JAK2/STAT5, stabilizing the complex. Neither total JAK2 nor STAT5 protein levels were affected, but we found that the state of phosphorylation of STAT5 (Tyr694) by JAK2 was HSP27 dependent. We demonstrated that HSP27, through interaction with STAT5, physically prevented its dephosphorylation by the phosphatase SHP2 in those cells.
In conclusion, HSP27 plays a very important role in STAT3/5 signaling, both in contexts of tumor development and others such as placenta development. In contrast with HSP90, whose functions depend on the client proteins, HSP27’s different functions (protein stability, phosphorylation, disruption of complex of proteins, etc.) may rely on the phosphorylation and oligomerization status of the chaperone (Figure 3). The general vision is mainly dichotomous: on one side there are large phosphorylated oligomers, and on the other nonphosphorylated dimers. This simplistic description does not reflect the reality of cellular dynamics. Future studies will be needed to specify the proportion of each HSP27 oligomer within the cells and the associated function.

**Figure 3.** Localization and described functions of HSP27 within the STAT3 and STAT5 signaling pathways. HSP27 state of oligomerization varies dynamically to modulate its binding capacity to target proteins in a context-dependent way. HSP27 directly interacts with pYSTAT3 and total STAT3 to promote stabilization and phosphorylation. HSP27 directly binds to JAK2\(^{V617F}\)/STAT5 complexes to prevent STAT5 dephosphorylation by SHP-2 in MPN. HSP27 also displaces multiprotein complexes like the STAT3/PKR complex.

5. **HSP110**

5.1. **HSP110 Structure**

The 110 kDa heat shock protein (HSP110), also known as HSP105 or HSPH1, belongs to the members of the HSPH family. Although it appears to be distinct from other HSPs (HSP27, HSP40, HSP70, and HSP90) because of its molecular weight and the specificity of certain sequences, HSP110 is a member of the family of HSP70 proteins [143,144]. Until quite recently, HSP110 was considered as a mere nucleotide exchange factor of HSP70. However, it is now well established that HSP110 is able to act as an unfolding chaperone on its own using ATP hydrolysis to lead to conversion of stable misfolded polypeptide substrates into natively refolded products, even when HSP70 is not present [145]. In an ATP-independent manner, HSP110 also has the antiaggregating properties of unfolded or misfolded proteins.
5.2. HSP110 Functions

In contrast to other chaperones, like HSP90 or HSP70, little is known about the cellular and extracellular functions of HSP110. It is a ubiquitous and conserved chaperone with antiaggregation capabilities that act in synergy with the refolding activity of HSP70, which contributes to efficient protein homeostasis [145,146]. HSP110 expression is induced by a wide array of stress including hyperthermia, ethanol, oxidative stress, recovery from anoxia (i.e., reperfusion injury), some anticancer drugs, and inflammation. HSP110 is approximately four-fold more efficient at binding and stabilizing denatured protein substrates than HSP70 [147]. Due to its strong chaperone (or holder) function, HSP110 is a very good antigen carrier. It is therefore used in vaccine formulations [148] as a recombinant chaperone vaccine for antigen-targeted cancer immunotherapy. These vaccines have generated robust antigen-specific T lymphocyte responses in different preclinical cancer models [149]. Two forms of HSP110 exist: HSP110α and an alternatively spliced form called HSP110β, which contains 43 fewer amino acids [150]. While HSP110α is constitutively expressed in the cytoplasm of cells and can be induced in stressful conditions such as heat shock, HSP110β is strictly heat-inducible and specifically localized in the nucleus (Figure 4) [151]. Beyond the different localization of these two forms of HSP110, their differential roles remain unclear. Like other HSP proteins, the expression of HSP110 can be induced by a number of physical or chemical sources of stress and depends on the heat shock factor 1 (HSF1) transcription factor. Moreover, the presence STAT3 on the HSP110 promoter has been recently reported in humans, suggesting its regulation by STAT3 [152]. Conversely, HSP110β can induce HSP70 expression through STAT3 in mammalian cells (Figure 4) [153]. It is now clearly established that HSP110 favors several signaling pathways, including the Wnt/β-Catenin, MyD88/TLR, and STAT3 pathways [154,155].

Concerning the STAT signaling pathway, we have demonstrated that HSP110 directly binds to STAT3 and favors its phosphorylation (Tyr705) by JAK2 in the cytosol, thereby promoting cell proliferation (Figure 4) [156]. Colon cancer cells in which HSP110 has been shRNA-mediated and knocked down hardly proliferate, but proliferation is reactivated by the re-expression of HSP110 in these cells. Tumors from patients with high levels of HSP110 show high STAT3 phosphorylation levels and strong expression of proliferation markers [154,156]. Therefore, both the protein homeostasis function and the role of HSP110 on proliferative pathways may explain why this protein is linked to aggressive tumors. We suggest that HSP110 expression could be a surrogate prognostic marker and a potential therapeutic target, particularly for treatment of carcinomas, particularly colorectal cancer, for which there is strong evidence.

Given the emerging role of HSP110 in cancer and its role on STAT3 in particular, we selected two foldamers upon screening of a chemical library based on their ability to inhibit and block recombinant HSP110-mediated antiaggregation activity and to disrupt HSP110–STAT3 interaction [72]. These compounds, named 33 and 52 (Table 1, Figure 5), inhibit HSP110 chaperone function and colorectal cancer growth in vitro and in vivo [72]. Altogether these results confirm the interest of targeting HSP110, at least in colorectal cancers, and probably in other types of cancer, such as B-cell lymphoma.

Although HSPs are generally considered intracellular proteins, we now know that HSP110 can also be released to act extracellularly like HSP27, 70, and 90 [157–159]. The release of HSP110 from human intestinal epithelial cells has also been described, suggesting a role in the physiological process of epithelial renewal [160]. More recently, we have demonstrated that HSP110, like other HSPs, can be secreted by cancer cells and is abundantly observed in the cancer microenvironment [161]. Interestingly, extracellular HSP110 affects macrophage differentiation/polarization by favoring a protumor, anti-inflammatory profile and the formation of tumor-associated macrophages (TAMs), which are associated with immune suppression. Furthermore, we found a correlation between the level of extracellular HSP110 and the number of TAMs in patient biopsies [161], suggesting that the effect of extracellular HSP110 function on macrophages may also contribute to the poor outcomes that are associated with HSP110 expression.
Due to its strong chaperone (or holder) function, HSP110 can be secreted by cancer cells and is abundantly observed in the cancer microenvironment, which are associated with immune suppression. Furthermore, we found a correlation between the expression of HSP110 and the formation of tumor-associated macrophages (TAMs), which are protumor, anti-inflammatory cells. HSP110, like other HSPs, can be secreted by cancer cells and is abundantly observed in the cancer microenvironment, containing 43 fewer amino acids. While HSP110 is constitutively expressed in the cytoplasm of human intestinal epithelial cells and can be induced in stressful conditions such as heat shock, HSP110 expression is induced by a wide array of stress including hyperthermia, ethanol, oxidative stress, recovery from anoxia (i.e., reperfusion injury), some protein homeostasis. HSP110 expression is induced by a wide array of stress including hyperthermia, ethanol, oxidative stress, recovery from anoxia (i.e., reperfusion injury), some protein homeostasis.

Tumors from patients with high levels of HSP110 show high STAT3 phosphorylation and proliferation (Figure 4). Colon cancer cells in which HSP110 has been shRNA-mediated and knocked down hardly proliferate, but proliferation is reactivated by the re-expression of HSP110 in these cells. Tumors from patients with high levels of HSP110 show high STAT3 phosphorylation and proliferation (Figure 4).

Altogether these results confirm the interest of targeting HSP110, at least in colorectal cancers, and probably in other types of cancer, such as B-cell lymphoma. Given the emerging role of HSP110 in cancer and its role on STAT3 in particular, we selected the HSP110 β-mediated HSP70 promoter. HSP70 directly interacts with STAT3 and its translocation to the nucleus. STAT3 binds to the sequence of the HSP70 promoter at the level of a sequence (~206 to ~187 base pair) whose mutation abrogated the activation of the HSP110 β-mediated HSP70 promoter. HSP70 directly interacts with STAT3 and STAT5. It favors STAT3 phosphorylation and activity, and STAT5 levels, phosphorylation, and activity.

The localization and described functions of HSP110 and HSP70 within the STAT3 and STAT5 signaling pathways. HSP110 directly binds to STAT3 in the cytosol and favors its phosphorylation through JAK2, and, through this mechanism, participates in the promotion of cell proliferation. HSP110α and HSP110β localize to the cytoplasm and nucleus of cells, respectively. HSP110β induces the expression of HSP70 in mammalian cells. Overexpression of HSP110β stimulated the phosphorylation of STAT3 (Tyr705) and its translocation to the nucleus. STAT3 binds to the sequence of the HSP70 promoter at the level of a sequence (~206 to ~187 base pair) whose mutation abrogated the activation of the HSP110 β-mediated HSP70 promoter. HSP70 directly interacts with STAT3 and STAT5. It favors STAT3 phosphorylation and activity, and STAT5 levels, phosphorylation, and activity.

Figure 4. Localization and described functions of HSP110 and HSP70 within the STAT3 and STAT5 signaling pathways. HSP110 directly binds to STAT3 in the cytosol and favors its phosphorylation through JAK2, and, through this mechanism, participates in the promotion of cell proliferation. HSP110α and HSP110β localize to the cytoplasm and nucleus of cells, respectively. HSP110β induces the expression of HSP70 in mammalian cells. Overexpression of HSP110β stimulated the phosphorylation of STAT3 (Tyr705) and its translocation to the nucleus. STAT3 binds to the sequence of the HSP70 promoter at the level of a sequence (~206 to ~187 base pair) whose mutation abrogated the activation of the HSP110 β-mediated HSP70 promoter. HSP70 directly interacts with STAT3 and STAT5. It favors STAT3 phosphorylation and activity, and STAT5 levels, phosphorylation, and activity.

Figure 5. Structure of the main small-molecule inhibitors of HSP27 (blue), HSP70 (Green), and HSP110 (Orange). RP101 can inhibit HSP27 function via direct binding to Phe29 and Phe33. VER-155008 binds to the ATP-binding site at the N-terminus of HSP70. Pifithrin-µ inhibits specifically function of HSP70 via direct binding to its substrate binding domain. Compounds 52 and 33 bind to the ATP binding site at the N-terminus of HSP110.
6. HSP70

6.1. HSP70 Structure

Stress-inducible HSP70 (also called HSP72 or HSP1A, HSPA1B) is another member of the HSP superfamily that has emerged as a viable and very promising target for development of antitumor drugs to combat various forms of cancer [162–164]. As the most ubiquitous stress-inducible chaperone, HSP70 exhibits numerous chaperone functions that are critical for both the folding and proteasomal degradation of misfolded proteins. It thus participates in cellular protein quality control systems, leading to cell homeostasis and survival during stress conditions. The human HSP70 protein family consists of at least 13 members, including stress-induced HSP70 and the heat shock cognate protein 70 (HSC70) [165]. The chaperone mechanism of HSP70 has been extensively studied [166]. HSP70 associates with misfolded proteins in a manner controlled by its ATPase cycle and cochaperones such as HSP40, BAG family proteins, HIP, HOP, and HSPBP1 [165].

6.2. HSP70 Functions

Based on immunoprecipitation analysis from normal rat kidney interstitial fibroblast (NRK-49F) cells, HSP70 has been shown to directly interact with multiple STAT proteins, including STAT3/5 (Figure 4). This interaction increased when cells were stressed by exposure to advanced glycation end product [167]. Although the data are still limited, studies show that manipulating HSP70 expression or activity affects STAT protein activity within cells. HSP70 (HSP701A/B) knock down using siRNA further decreased constitutive STAT3 activity in an acute myeloid leukemia cell line (HEL) treated with arsenic trioxide and the HSP90 inhibitor 17-DMAG [168]. In addition, increasing HSP70 activity with administration of geranylgeranylacetone before and three days after intracerebral hemorrhage resulted in increased STAT3 and AKT phosphorylation and also cerebral levels of eNOS, which are collectively associated with preserved cerebral blood flow, decreased neuronal cell death, and improved functional recovery in rats [169]. Uchida et al. suggested that the mechanism for HSP70 induction through geranylgeranylacetone may be the result of geranylgeranylacetone-induced induction of protein kinase C [170].

It is worth noting that upregulation of HSP70 could stimulate cell proliferation through the control of tyrosine kinase functions. In cancer cells derived from chronic myeloid leukemia cells, BCR-ABL tyrosine kinase activity results in the phosphorylation and activation of AKT, and in the phosphorylation and DNA-binding activity of STAT5, which leads in turn to an increase in the expression of antiapoptotic protein Bcl-xL [171]. Interestingly, while increased expression of HSP70 results in the upregulation of STAT5 level and activity, inhibition of the BCR-ABL tyrosine kinase activity with imatinib or inhibition of PI-3K activity with wortmannin both result in a decrease in HSP70 expression and STAT5 activity. Thus, uncontrolled cell signaling may result in the transcription of HSP70, which in turn regulates the level and activity of STAT5 (Figure 4) [171]. Besides the intracellular role of HSP70 as a survival factor that promotes tumorigenesis [172], it is now known that HSP70 also regulates diverse immunoregulatory activities such as antigen cross presentation [173,174], dendritic cell maturation [175,176], and natural killer cell [177,178] and myeloid-derived suppressor cell [179] activities, by acting extracellularly as a cytokine [180,181]. We demonstrated that membrane-associated HSP70 is found extracellularly in tumor-derived exosomes and that it restrained tumor immune surveillance by promoting myeloid-derived suppressor cell functions in both mice and humans. Interestingly, tumor-derived exosomes harboring HSP70 were found to mediate the suppressive activity of the myeloid-derived suppressor cells via activation of STAT3 and ERK [179].
7. Regulation Mechanisms of HSF/HSPs by JAK/STAT Signaling: A Feedback Loop?

7.1. HSF and SOCS Regulation

The activation of the JAK family and the subsequent STAT signaling is regulated by the family of suppressors of cytokine signaling (SOCS) proteins. This system aims to protect organisms from permanent and/or overstimulation that could lead, for instance, to severe systemic inflammations mediated by IFN-γ signaling [182]. Conversely, a deficit in SOCS expression could play a pivotal role in the development and progression of cancers [183]. Expression of SOCS3, which has been shown to inhibit JAK1, JAK2, and TYK2 [184], is frequently reduced in cancer cells, thereby leading to a growth advantage. The effect of HSF1 and HSP on SOCS3 expression changes depending on the tissue and whether the context is normal or tumoral. In nontumoral microglia cells, the activation of HSF1 by paoniflorin induced an indirect increase of SOCS3 expression mediated by HSP70 production and autocrine action [185]. Conversely, it was recently shown that HSF1 could directly bind to the SOCS3 promoter region and inhibit the transcriptional activity of its promoter [186]. This reinforces the role of HSF1 as a transcription factor for many genes not related to heat shock response [3]. SOCS3 repression of expression can also be mediated by HSPs, as seen in chronic lymphocytic leukemia. In this context, HSP90 inhibition by 17-DMAG induces the expression of SOCS3 through the activation of the p38 MAPK signaling [34]. This regulation is probably specific to tumors, as normal B cells were not found to upregulate SOCS3 expression upon HSP90 inhibition, and their migration was not affected [34].

7.2. HSF/HSPs and JAK/STAT

The regulation of the STAT signaling pathway by HSPs has been largely described, but in a positive feedback loop STAT3/5 has been shown to regulate HSPs. Little is known about HSP regulation apart from the fundamental role of HSF. The STAT3/5 pathway modulates expression of HSP27, HSP70, HSP90, and HSP110 when faced with different stressful stimuli [187]. Among those, mild heat shock is a type of stress (that was used to first describe the function of HSPs) during which the induction of HSPs prevents cell death from intense heat shock that otherwise would have been lethal. This thermotolerance is also accompanied by STAT3 phosphorylation. Inhibition of STAT3 activation by STAT3 inhibitors AG490 or static partially suppresses thermotolerance and HSP110 expression, but not HSP70 and HSP27 [188]. This result underlines a particular role for HSP110 in the process, which is in line with its capacity to interact with α-tubulin. This mechanism could therefore protect microtubules from severe heat shock [189]. Besides STAT3, STAT1 is also involved in HSP70 and HSP90 regulation, particularly after IFN-γ activation [190,191] or under heat shock [192]. Together with HSF1, STAT1 is recruited to the first intron of the HSP90β gene to favor the recruitment of a chromatin-remodeling complex, leading to enhanced HSP90β expression.

Other types of stress, such as hypoxic stress (a common phenomenon in a majority of tumors), are strong inducers of HSP90α expression. In these conditions, STAT3 is one of the transcription factors that regulate HSP90α, and hypoxia increases the binding of STAT5 to the HSP90α promoter [193]. When the STAT signaling pathway is constitutively active in tumors, like in breast and colon cancer, STAT3 has also been shown to transcriptionally induce HSP27 expression [194]. Though less documented, this mechanism also exists in hematological malignancies like Burkitt’s lymphoma, where pharmacological inhibition of STAT3 by AG490 downregulates HSP70 expression [195].

8. Conclusions

We have reviewed here the multiple roles of HSPs in the STAT3/5 activation network. From receptor tyrosine kinases to promoter binding of STAT3/5 target genes, HSPs appear to use several mechanisms to control this pathway. Among the various HSPs, HSP90 has a central role in the cellular machinery and is one of the most abundant cytosolic proteins. This role is clearly exposed when we describe both kinases and STAT proteins as HSP90 client proteins. The current literature points to the important role of HSP90/STAT3/STAT5 in cancer growth and the ability to thwart chemotherapy [3,196–198].
This discovery has prompted the development of drugs specifically targeting HSP90 and the subsequent initiation of clinical trials for cancer patients (Table 1, Figure 2). Almost all of the trials have reported clinical responses, confirming the relevance of this strategy. However, adverse side-effects were also frequent due to the inherent toxicity of HSP90 inhibitors. This could be explained by the number of client proteins that are simultaneously chaperoned by HSP90, which obviously endangers critical physiological processes in normal cells. A strategic question emerges from this observation: should we continue searching for more specific, less toxic drugs? Or should we limit studies to fundamental science to uncover new biological mechanisms? Other HSPs are gaining interest in the scientific community. In particular, HSP110 is a newly discovered player in the field of cancer aggressiveness that controls the STAT3 pathway in colon cancers and in B-cell lymphomas. Our team recently identified the first HSP110 inhibitors (Table 1, Figure 5) that block interaction with STAT3 and that effectively limit colon cancer progression in mouse models; we plan to bring these to the clinic within the next few years. No toxicity has been demonstrated so far, and we believe this new type of inhibitor is promising for cancers whose poor prognosis is associated with HSP110/pYSTAT3 expression. Both intra- and extracellular HSP70, which belong to a related HSP family, favor STAT3/5 phosphorylation by JAK2. This dual action is of particular therapeutic interest since targeting HSP70 would simultaneously blunt the macrophage-mediated immunosuppression and block the intratumoral growth signal. To reach the goal of bringing HSP70 inhibitors to the clinic, we have identified peptide aptamers that bind to the peptide-binding domain of HSP70. This has not been an easy task since HSP70, contrary to HSP90, is not a “druggable” protein. Despite this limitation, our HSP70 inhibitors are specific and have proven effective in xenograft models of colon cancer. Of course, further studies will be needed before clinical trials can be initiated. Finally, HSP27 has recently been found to play new roles in myeloproliferative neoplasms. In this disease, which is driven by the JAK2V617F/STAT5 pathway, HSP27 inhibition destabilizes the protein complex and limits disease related myelofibrosis. Furthermore, in contrast to HSP90 inhibitors, the HSP27 inhibitor does not induce the compensatory expression of other HSPs that usually account for resistance to treatment. Targeting HSP27 would therefore be an alternative to the failed HSP90 therapy, which also targeted JAK2V617F. An oligonucleotide antisense of second generation (OGX427) is currently under clinical evaluation (Table 1).

Furthermore, small molecules targeting STAT3/5 have been identified as enhancing protein degradation. The inhibition of STAT pathways is therefore likely highly amenable to HSP inhibition and presents a potential synergistic therapeutic strategy (Table 1).

In conclusion, we show in this review that the STAT3/5 pathways rely on multiple HSPs under physiological and pathological conditions. Targeting various members of the HSP family, alone or in combination, will probably improve the inhibition of this central pathway and should foster the development of new, more specific and less toxic HSP inhibitors to complete the existing therapeutic arsenal.

Author Contributions: G.J., F.H. co-wrote the paper, and designed and drew all the figures for this manuscript. C.G. proofread the manuscript, gave suggestions, and modified the language. F.G. contributed to the editing and critical reading of the manuscript. All authors have read and approved the final manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by a French Government grant managed by the French National Research Agency under the program “Investissements d’Avenir” with reference ANR-11-LABX-0021 (LabEX LipSTIC), the Institut National du Cancer, the Agence Nationale de la Recherche, the Conseil Régional de Bourgogne, the European Union through the PO FEDER-FSE Bourgogne 2014/2020 programs, and the association “Châlon-sur-Saône Tulipes contre le cancer”.

Acknowledgments: The authors thank S. Rankin (Dijon University Hospital) for proofreading the manuscript. F. Hermetet was supported by a fellowship from the University of Burgundy and Franche-Comté through the ISITE-BFC program. C Garrido’s team is labeled by La Ligue Nationale contre le Cancer.

Conflicts of Interest: The authors declare no conflict of interest.
Cancers 2020, 12, 21

References

1. Sorger, P.K. Heat shock factor and the heat shock response. Cell 1991, 65, 363–366. [CrossRef]
2. Welch, W.J. Heat shock proteins functioning as molecular chaperones: Their roles in normal and stressed cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1993, 339, 327–333. [PubMed]
3. Baylot, V.; Andrieu, C.; Katsogiannou, M.; Taieb, D.; Garcia, S.; Giusianom, S.; Acunzo, J.; Iovanna, J.; Sorger, P.K. Heat shock factor and the heat shock response. Cell 2007, 81, 15–27. [CrossRef] [PubMed]
4. Heinrich, J.C.; Tuukkanen, A.; Seigneuric, R.; Garrido, C. Targeting heat shock proteins in cancer. Cancer Lett. 2013, 332, 275–285. [CrossRef] [PubMed]
5. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
6. Calderwood, S.K.; Gong, J. Heat Shock Proteins Promote Cancer: It’s a Protection Racket. Trends BioChem. Sci. 2016, 41, 311–323. [CrossRef] [PubMed]
7. Lianos, G.D.; Alexiou, G.A.; Mangano, A.; Mangano, A.; Rausei, S.; Boni, L.; Dionigi, G.; Roukos, D.H. The role of heat shock proteins in cancer. Cancer Lett. 2015, 360, 114–118. [CrossRef]
8. Wu, J.; Liu, T.; Rios, Z.; Mei, Q.; Lin, X.; Cao, S. Heat Shock Proteins and Cancer. Trends Pharmacol. Sci. 2017, 38, 226–256. [CrossRef]
9. Guttmann, D.M.; Koumenis, C. The heat shock proteins as targets for radiosensitization and chemosensitization in cancer. Cancer Biol. Ther. 2011, 12, 1023–1031. [CrossRef]
10. Song, T.F.; Zhang, Z.F.; Liu, T.; Yang, T.; Jiang, J.; Li, P. Small interfering RNA-mediated silencing of heat shock protein 27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J. Cancer Res. Clin. Oncol. 2011, 137, 1349–1361. [CrossRef]
21. Kaiser, M.; Kühnl, A.; Reins, J.; Fischer, S.; Ortiz-Tanchez, J.; Schlee, C.; Mochmann, L.H.; Heesch, S.; Benlasfer, O.; Hofmann, W.K.; et al. Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia. Blood Cancer J. 2011, 1, e28. [CrossRef] [PubMed]

22. Goloudina, A.R.; Demidov, O.N.; Garrido, C. Inhibition of HSP70: A challenging anti-cancer strategy. Cancer Lett. 2012, 325, 117–124. [CrossRef] [PubMed]

23. Massey, A.J.; Williamson, D.S.; Browne, H.; Murray, J.B.; Dokurno, P.; Shaw, T.; Macias, A.T.; Daniels, Z.; Geoffroy, S.; Delpop, M.; et al. A novel small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer ChemoTher. Pharmacol. 2010, 66, 535–545. [CrossRef] [PubMed]

24. Brünnert, D.; Langer, C.; Zimmermann, L.; Bargou, R.C.; Burchardt, M.; Chatterjee, M.; Stope, M.B. The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90β and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth. J. Cell BioChem. 2020, 121, 407–417. [CrossRef] [PubMed]

25. Chatterjee, M.; Andrulis, M.; Stühmer, T.; Müller, E.; Hofmann, C.; Steinbrunn, T.; Heimberger, T.; Schraud, H.; Kressmann, S.; Einsele, H.; et al. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2013, 98, 1132–1141. [CrossRef] [PubMed]

26. Rérole, A.L.; Gobbo, J.; De Thonel, A.; Schmitt, E.; Pais de Barros, J.P.; Hammann, A.; Lanneau, D.; Fourmaux, E.; Demidov, O.N.; Micheau, O.; et al. Peptides and aptamers targeting HSP70: A novel approach for anticancer chemotherapy. Cancer Res. 2011, 71, 484–495. [CrossRef]

27. Schmitt, E.; Maingret, L.; Puig, P.E.; Rérole, A.L.; Ghiringhelli, F.; Hammann, A.; Solary, E.; Kroemer, G.; Garrido, C. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006, 66, 4191–4197. [CrossRef]

28. Stangl, S.; Gehrmann, M.; Riegger, J.; Kuhls, K.; Riederer, I.; Sievert, W.; Hube, K.; Mocikat, R.; Dressel, R.; Kremmer, E.; et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc. Natl. Acad. Sci. USA 2011, 108, 733–738. [CrossRef]

29. Krause, S.W.; Gastpar, R.; Andreesen, R.; Gross, C.; Ulrich, H.; Thonigs, G.; Pfister, K.; Multhoff, G. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: A clinical phase i trial. Clin. Cancer Res. 2004, 10, 3699–3707. [CrossRef]

30. Shiotsu, Y.; Neckers, L.M.; Wortman, I.; An, W.G.; Schulte, T.W.; Soga, S.; Murakata, C.; Tamaoki, T.; Akinaga, S. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G (1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 2000, 96, 2284–2291. [CrossRef]

31. Palacios, C.; López-Pérez, A.I.; López-Rivas, A. Down-regulation of RIP expression by 17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes TRAIL-induced apoptosis in breast tumor cells. Cancer Lett. 2010, 287, 207–215. [CrossRef] [PubMed]

32. Schaefer, S.; Svenstrup, T.H.; Guerra, B. The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells. PLoS ONE 2017, 12, e0177706. [CrossRef] [PubMed]

33. Ayrault, O.; Godeny, M.D.; Dillon, C.; Zindy, F.; Fitzgerald, P.; Roussel, M.F.; Beere, H.M. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma. Proc. Natl. Acad. Sci. USA 2009, 106, 17037–17042. [CrossRef] [PubMed]

34. Chen, T.L.; Gupta, N.; Lehman, A.; Ruppert, A.S.; Yu, L.; Oakes, C.C.; Claus, R.; Plass, C.; Maddocks, K.J.; Andritsos, L.; et al. Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. Oncotarget 2016, 7, 28684–28696. [CrossRef]

35. Hanson, B.E.; Vesole, D.H. Retaspimycin hydrochloride (IPI-504): A novel heat shock protein inhibitor as an anticancer agent. Expert Opin. Investig. Drugs 2009, 18, 1375–1383. [CrossRef]

36. Song, D.; Chaerkady, R.; Tan, A.C.; Garcia-García, E.; Nalli, A.; Suárez-Gauthier, A.; López-Ríos, F.; Zhang, X.F.; Solomon, A.; Tong, J.; et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol. Cancer Ther. 2008, 7, 3275–3284. [CrossRef]
37. Wagner, A.J.; Chugh, R.; Rosen, L.S.; Morgan, J.A.; George, S.; Gordon, M.; Dunbar, J.; Normant, E.; Grayzel, D.; Demetri, G.D.; et al. A phase I study of the HSP90 inhibitor retasipimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin. Cancer Res. 2013, 19, 6020–6029. [CrossRef]

38. Scaltriti, M.; Serra, V.; Normant, E.; Guzman, M.; Rodriguez, O.; Lim, A.R.; Slocum, K.L.; West, K.A.; Rodriguez, V.; Prudkin, L.; et al. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol. Cancer Ther. 2011, 10, 817–824. [CrossRef]

39. Floris, G.; Debiec-Rychter, M.; Wozniak, A.; Stefan, C.; Normant, E.; Faa, G.; Machiels, K.; Vanleeuw, U.; Sciot, R.; Schöffski, P. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol. Cancer Ther. 2011, 10, 1897–1908. [CrossRef]

40. Normant, E.; Paez, G.; West, K.A.; Lim, A.R.; Sclocum, K.L.; Tunkey, C.; McDougall, J.; Wylie, A.A.; Robison, K.; Caliri, K.; et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011, 30, 2581–2586. [CrossRef]

41. Hendriks, L.E.L.; Dingemans, A.C. Heat shock protein protein antagonists in early stage clinical trials for NSCLC. Expert Opin. Investig. Drugs 2017, 26, 541–550. [CrossRef] [PubMed]

42. Wu, L.X.; Xu, J.H.; Zhang, K.Z.; Lin, Q.; Huang, X.W.; Wen, C.X.; Chen, Y.Z. Disruption of the Bcr-Abl/Hsp90 protein complex: A possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 2008, 22, 1402–27. [CrossRef] [PubMed]

43. Shelton, S.N.; Shawgo, M.C.; Matthews, S.B.; Lu, Y.; Donnelly, A.C.; Szabla, K.; Tanol, M.; Vielhauer, G.A.; Rajewski, R.A.; Mats, R.L.; et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol. Pharmacol. 2009, 76, 1314–1322. [CrossRef] [PubMed]

44. Matthews, S.B.; Vielhauer, G.A.; Manthe, C.A.; Chaguturu, V.K.; Szabla, K.; Mats, R.L.; Donnelly, A.C.; Blagg, B.S.; Holzbeierlein, J.M. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 2010, 70, 27–36. [CrossRef]

45. Le, H.T.; Vielhauer, G.A.; Manthe, C.A.; Chaguturu, V.K.; Szabla, K.; Mats, R.L.; Donnelly, A.C.; Blagg, B.S.; Holzbeierlein, J.M. Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells. Cancer Lett. 2018, 412, 297–307. [CrossRef]

46. Lin, S.F.; Lin, J.D.; Hsueh, C.; Chou, T.C.; Ye, C.N.; Chen, M.H.; Wong, R.J. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. Oncotarget 2017, 8, 41294–41304. [CrossRef]

47. Lee, H.; Saini, N.; Howard, E.W.; Parris, A.B.; Ma, Z.; Zhao, Q.; Zhao, M.; Liu, B.; Edgerton, S.M.; Thor, A.D.; et al. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. Sci. Rep. 2018, 8, 6829. [CrossRef]

48. He, W.; Hu, H. BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review). Oncol. Rep. 2018, 40, 3–15. [CrossRef]

49. Marubayashi, S.; Koppikar, P.; Taldone, T.; Abdel-Wahab, O.; West, N.; Bhagwat, N.; Caldas-Lopes, E.; Ross, K.N.; Gonen, M.; Gozman, A.; et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J. Clin. Investig. 2010, 120, 3578–3593. [CrossRef]

50. Fiskus, W.; Verstovsek, S.; Manshouri, T.; Rao, R.; Balusu, R.; Venkannagari, S.; Rao, N.N.; Ha, K.; Smith, J.E.; Hembruff, S.L.; et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin. Cancer Res. 2011, 17, 7347–7358. [CrossRef]

51. Park, K.S.; Hong, Y.S.; Choi, J.; Yoon, S.; Kang, J.; Kim, D.; Lee, K.P.; Im, H.S.; Lee, C.H.; Seo, S.; et al. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. BMB Rep. 2018, 51, 660–665. [CrossRef] [PubMed]

52. Yang, H.; Lee, M.H.; Park, I.; Jeon, H.; Choi, J.; Seo, S.; Kim, S.W.; Koh, G.Y.; Park, K.S.; Lee, D.H. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. Cancer Lett. 2017, 411, 19–26. [CrossRef] [PubMed]

53. Kim, S.H.; Kang, J.G.; Kim, C.S.; Ihm, S.H.; Choi, M.G.; Yoo, H.J.; Lee, S.J. The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells. Tumour. Biol. 2017, 39, 1010428317722068. [CrossRef] [PubMed]
54. Brough, P.A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J.E.; Cheung, K.M.; Collins, I.; Davies, N.G.; Drysdale, M.J.; et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51, 196–218. [CrossRef] [PubMed]

55. Liu, J.; Sun, W.; Dong, W.; Wang, Z.; Qin, Y.; Zhang, T.; Zhang, H. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells. Biochem. Biophys. Res. Commun. 2017, 487, 313–319. [CrossRef]

56. Tao, W.; Chakraborty, S.N.; Leng, X.; Ma, H.; Arlinghaus, R.B. HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells. Genes Cancer 2015, 6, 19–29.

57. Chakraborty, S.N.; Leng, X.; Perazzona, B.; Sun, X.; Lin, Y.H.; Arlinghaus, R.B. Combination of JAK2 and HSP90 inhibitors: An effective therapeutic option in drug-resistant chronic myelogenous leukemia. Genes Cancer 2016, 7, 201–208.

58. Hobbs, G.S.; Hanasoge Somasundara, A.V.; Kleppe, M.; Litvin, R.; Arcila, M.; Ahn, J.; McKenney, A.S.; Knapp, K.; Ptaszkin, R.; Weinstein, H.; et al. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. Haematologica 2018, 103, e5–e9. [CrossRef]

59. Johnson, M.L.; Yu, H.A.; Hart, E.M.; Weitner, B.B.; Rademaker, A.W.; Patel, J.D.; Kris, M.G.; Riely, G.J. Phase I-II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J. Clin. Oncol. 2015, 33, 1666–1673. [CrossRef]

60. Weigert, O.; Lane, A.A.; Bird, L.; Kopp, N.; Chapuy, B.; van Bodegom, D.; Toms, A.V.; Marubayashi, S.; Christie, A.L.; McKeown, M.; et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J. Exp. Med. 2012, 209, 259–273. [CrossRef]

61. Mahendrarajah, N.; Borisova, M.E.; Reichardt, S.; Godmann, M.; Sellmer, A.; Mahboobi, S.; Haitel, A.; Schmid, K.; Kenner, L.; Heinzl, T.; et al. HSP90 is necessary for the ACK1-dependent phosphorylation of STAT1 and STAT3. Cell Signal. 2017, 39, 9–17. [CrossRef] [PubMed]

62. Smyth, T.; Paraiko, K.H.T.; Hearns, K.; Rodríguez-Lopez, A.M.; Munck, J.M.; Haarberg, H.E.; Sondak, V.K.; Thompson, N.T.; Azab, M.; Lyons, J.F.; et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol. Cancer Ther. 2014, 13, 2793–2804. [CrossRef] [PubMed]

63. Graham, B.; Curry, J.; Smyth, T.; Fazal, L.; Feltell, R.; Harada, I.; Coyle, J.; Williams, B.; Reule, M.; Angove, H.; et al. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci. 2012, 103, 522–527. [CrossRef] [PubMed]

64. Courtin, A.; Smyth, T.; Hearns, K.; Saini, H.K.; Thompson, N.T.; Lyons, J.F.; Wallis, N.G. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upFront combination with the HSP90 inhibitor onalespib. Br. J. Cancer 2016, 115, 1069–1077. [CrossRef] [PubMed]

65. Eroglu, Z.; Chen, Y.A.; Gibney, G.T.; Weber, J.S.; Kudchadkar, R.R.; Khushalani, N.I.; Markowitz, J.; Brohl, A.S.; Tetteh, L.F.; Ramadan, H.; et al. Combined BRAF and HSP90 Inhibition in Patients with Unresectable. Clin. Cancer Res. 2018, 24, 5516–5524. [CrossRef] [PubMed]

66. Friedman, J.A.; Wise, S.C.; Hu, M.; Gouveia, C.; Vander Broek, R.; Freudlsperger, C.; Kannabiran, V.R.; Arun, P.; Mitchell, J.B.; Chen, Z.; et al. HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma. Transl. Oncol. 2013, 6, 429–441. [CrossRef] [PubMed]

67. Rice, J.W.; Veal, J.M.; Barabasz, A.; Foley, B.; Fadden, P.; Scott, A.; Huang, K.; Steed, P.; Hall, S. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib. Oncol. Res. 2009, 18, 229–242. [CrossRef]

68. Smith, D.L.; Acquaviva, J.; Sequeira, M.; Jimenez, J.P.; Zhang, C.; Sang, J.; Bates, R.C.; Proia, D.A. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target. Oncol. 2015, 10, 235–245. [CrossRef]

69. Moulick, K.; Ahn, J.H.; Zong, H.; Rodina, A.; Cerchietti, L.; Gomes DaGama, E.M.; Caldas-Lopes, E.; Beebe, K.; Perina, F.; Hatzì, K.; et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat. Chem. Biol. 2011, 7, 818–826. [CrossRef]
70. Hong, Y.S.; Jang, W.J.; Chun, K.S.; Jeong, C.H. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR. *Oncol. Rep.* 2014, 31, 2619–2624. [CrossRef] [PubMed]

71. Kobayashi, N.; Toyooka, S.; Soh, J.; Yamamoto, H.; Dote, H.; Kawasaki, K.; Otani, H.; Kubo, T.; Jida, M.; Ueno, T.; et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. *Lung Cancer* 2012, 75, 161–166. [CrossRef] [PubMed]

72. Gozzi, G.J.; Gonzalez, D.; Boudesco, C.; Dias, A.M.M.; Gotthard, G.; Uyanik, B.; Dondaine, L.; Marcion, G.; Hermetet, F.; Denis, C.; et al. Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy. *Cell Death Differ.* 2019. [CrossRef] [PubMed]

73. McClellan, A.J.; Xia, Y.; Deutschbauer, A.M.; Davis, R.W.; Gerstein, M. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. *Cell* 2007, 131, 121–135. [CrossRef] [PubMed]

74. Taipale, M.; Krykbaeva, I.; Koeva, M.; Kayatekin, C.; Westover, K.D.; Karras, G.I.; Lindquist, S. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. *Cell* 2012, 150, 987–1001. [CrossRef]

75. Makhnevych, T.; Houry, W.A. The role of Hsp90 in protein complex assembly. *Biochim. Biophys. Acta* 2012, 1823, 674–682. [CrossRef] [PubMed]

76. Boczek, E.E.; Reefschläger, L.G.; Dehling, M.; Struller, T.J.; Häusler, E.; Seidl, A.; Kaila, V.R.; Buchner, J. Conformational processing of oncogenic v-Src kinase by the molecular chaperone Hsp90. *Proc. Natl. Acad. Sci. USA* 2015, 112, E3189–E3198. [CrossRef] [PubMed]

77. Gray, P.J.; Prince, T.; Cheng, J.; Stevenson, M.A.; Calderwood, S.K. Targeting the oncogene and kinome chaperone CDC37. *Nat. Rev. Cancer* 2008, 8, 491–495. [CrossRef]

78. Shang, L.; Tomasi, T.B. The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. *J. Biol. Chem.* 2006, 281, 1876–1884. [CrossRef]

79. Peeters, P.; Wlodarska, I.; Baens, M.; Criel, A.; Selleslag, D.; Hagemeijer, A.; Van den Berghe, H.; Marynen, P. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. *Cancer Res.* 1997, 57, 564–569.

80. Lacronique, V.; Boureux, A.; Valle, V.D.; Poirel, H.; Quang, C.T.; Mauchaué, M.; Berthou, C.; Lessard, M.; Berger, R.; Ghysdael, J.; et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. *Science* 1997, 278, 1309–1312. [CrossRef]

81. Baxter, E.J.; Scott, L.M.; Campbell, P.J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G.S.; Bench, A.J.; Boyd, E.M.; Curtin, N.; et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet* 2005, 365, 1054–1061. [CrossRef] [PubMed]

82. Levine, R.L.; Loriaux, M.; Huntly, B.J.; Loh, M.L.; Beran, M.; Stoffregen, E.; Berger, R.; Clark, J.J.; Willis, S.G.; Nguyen, K.T.; et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid Leukemia but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. *Blood* 2005, 106, 3377–3379. [CrossRef] [PubMed]

83. James, C.; Ugo, V.; Le Couédic, J.P.; Staerck, J.; Delhommeau, F.; Lacout, C.; Garçon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. *Nature* 2005, 434, 1144–1148. [CrossRef] [PubMed]

84. Jones, A.V.; Kreil, S.; Zoi, K.; Waghorn, K.; Curtis, C.; Zhang, L.; Score, J.; Seear, R.; Chase, A.J.; Grand, F.H.; et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. *Blood* 2005, 106, 2162–2168. [CrossRef]

85. Bareng, J.; Jilani, I.; Gorre, M.; Kantarjian, H.; Giles, F.; Hannah, A.; Albitar, M. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. *Leuk. Lymphoma* 2007, 48, 2189–2195. [CrossRef]

86. Sen, B.; Johnson, F.M. Regulation of SRC family kinases in human cancers. *J. Signal. Transduct.* 2011, 2011, 865819. [CrossRef]

87. Garcia, R.; Bowman, T.L.; Niu, G.; Yu, H.; Minton, S.; Muro-Cacho, C.A.; Cox, C.E.; Falcone, R.; Fairclough, R.; Parsons, S.; et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. *Oncogene* 2001, 20, 2499–2513. [CrossRef]
88. Frame, M.C. Src in cancer: Deregulation and consequences for cell behaviour. *Biochim. Biophys. Acta* **2002**, *1602*, 114–130. [CrossRef]

89. Takeya, T.; Hanafusa, H. Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus. *Cell* **1983**, *32*, 881–890. [CrossRef]

90. Stehelin, D.; Varmus, H.E.; Bishop, J.M.; Vogt, P.K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. *Nature* **1976**, *260*, 170–173. [CrossRef]

91. Hunter, T.; Sefton, B.M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. *Proc. Natl. Acad. Sci. USA* **1980**, *77*, 1311–1315. [CrossRef]

92. Xu, Y.; Lindquist, S. Heat-shock protein hsp90 governs the activity of pp60v-src kinase. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 7074–7078. [CrossRef]

93. Whitesell, L.; Mimnaugh, E.G.; De Costa, B.; Myers, C.E.; Neckers, L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 8324–8328. [CrossRef]

94. Nathan, D.F.; Lindquist, S. Mutational analysis of Hsp90 function: Interactions with a steroid receptor and a protein kinase. *Mol. Cell Biol.* **1995**, *15*, 3917–3925. [CrossRef]

95. Luo, Q.; Boczek, E.E.; Wang, Q.; Buchner, J.; Kaila, V.R. Hsp90 dependence of a kinase is determined by its conformational landscape. *Sci. Rep.* **2017**, *7*, 43996. [CrossRef]

96. Verba, K.A.; Wang, R.Y.; Arakawa, A.; Liu, Y.; Shirouzu, M.; Yokoyama, S.; Agard, D.A. Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase. *Science* **2016**, *352*, 1542–1547. [CrossRef]

97. Giannini, A.; Bijlmakers, M.J. Regulation of the Src family kinase Lck by Hsp90 and ubiquitination. *Mol. Cell Biol.* **2004**, *24*, 5667–5676. [CrossRef]

98. Scholz, G.M.; Hartson, S.D.; Cartledge, K.; Volk, L.; Mats, R.L.; Dunn, A.R. The molecular chaperone Hsp90 is required for signal transduction by wild-type Hck and maintenance of its constitutively active counterpart. *Cell Growth Differ.* **2001**, *12*, 409–417.

99. Mahajan, N.P.; Whang, Y.E.; Mohler, J.L.; Earp, H.S. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: Role of Ack1 in polyubiquitination of tumor suppressor Wwox. *Cancer Res.* **2005**, *65*, 10514–10523. [CrossRef]

100. Karachaliou, N.; Pilotto, S.; Teixidó, C.; Viteri, S.; González-Cao, M.; Riso, A.; Morales-Espinosa, D.; Molina, M.A.; Chaib, I.; Santarpia, M.; et al. Melanoma: Oncogenic drivers and the immune system. *Ann. Transl. Med.* **2015**, *3*, 265. [CrossRef]

101. Da Rocha Dias, S.; Friedlos, F.; Light, Y.; Springer, C.; Workman, P.; Marais, R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. *Cancer Res.* **2005**, *65*, 10686–10691. [CrossRef]

102. Jabbour, E.; Kantarjian, H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. *Am. J. Hematol.* **2018**, *93*, 442–459. [CrossRef]

103. Coppo, P.; Friedlos, F.; Light, Y.; Springer, C.; Workman, P.; Marais, R. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. *Br. J. Haematol.* **2006**, *134*, 171–179. [CrossRef]

104. Nair, R.R.; Tolentino, J.H.; Eap, H.S. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: Role of Ack1 in polyubiquitination of tumor suppressor Wwox. *Cancer Res.* **2005**, *65*, 10514–10523. [CrossRef]

105. De Groot, R.P.; Raaijmakers, J.A.; Lammers, J.W.; Jove, R.; Koenderman, L. STAT5 activation by BCR-ABL contributes to transformation of K562 leukemia cells. *Blood* **1999**, *94*, 1108–1112. [CrossRef]

106. Sillaber, C.; Gesbert, F.; Frank, D.A.; Sattler, M.; Griffin, J.D. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. *Blood* **2000**, *95*, 2118–2125. [CrossRef]

107. Hoelzl, A.; Schuster, C.; Kovacic, B.; Zhu, B.; Wickre, M.; Hoelzl, M.A.; Fajmann, S.; Grebien, F.; Warsch, W.; Stengl, G.; et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. *EMBO Mol. Med.* **2010**, *2*, 98–110. [CrossRef]

108. Esfahani, K.; Cohen, V. HSP90 as a novel molecular target in non-small-cell lung cancer. *Lung Cancer (Auckl)* **2016**, *7*, 11–17.

109. Lemmon, M.A.; Schlessinger, J. Cell Signaling by receptor tyrosine kinases. *Cell* **2010**, *141*, 1117–1134. [CrossRef]
110. Kosack, L.; Wingelhofer, B.; Popa, A.; Orlova, A.; Agerer, B.; Vilagos, B.; Majek, P.; Parapatics, K.; Lercher, A.; Ringler, A.; et al. The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease. *Cancer Cell* 2019, 35, 125–139.e9. [CrossRef]

111. Xu, W.; Mimnaugh, E.G.; Kim, J.S.; Trepel, J.B.; Neckers, L.M. Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2. *Cell Stress Chaperones* 2002, 7, 91–96. [CrossRef]

112. Peng, X.; Guo, X.; Borkan, S.C.; Bharti, A.; Kuramochi, Y.; Calderwood, S.; Sawyer, D.B. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. *J. Biol. Chem.* 2005, 280, 13148–13152. [CrossRef] [PubMed]

113. Wee, P.; Wang, Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers (Basel)* 2017, 9, 52. [CrossRef]

114. Bao, R.; Lai, C.J.; Wang, D.G.; Qu, H.; Yin, L.; Zifcak, B.; Tao, X.; Wang, J.; Attyyan, R.; Samson, M.; et al. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. *Mol. Cancer Ther.* 2009, 8, 3296–3306. [CrossRef]

115. Ono, N.; Yamazaki, T.; Tsukaguchi, T.; Fujii, T.; Sakata, K.; Suda, A.; Tsukuda, T.; Mio, T.; Ishii, N.; Konoh, O.; et al. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. *Cancer Sci.* 2013, 104, 1346–1352. [CrossRef]

116. Sato, N.; Yamamoto, T.; Sekine, Y.; Yumioka, T.; Junicho, A.; Fuse, H.; Matsuda, T. Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3. *Biochem. Biophys. Res. Commun.* 2003, 300, 847–852. [CrossRef]

117. Song, S.; Su, Z.; Xu, H.; Niu, M.; Chen, X.; Min, H.; Zhang, B.; Sun, G.; Xie, S.; Wang, H.; et al. Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. *Cell Death Dis.* 2017, 8, e2612. [CrossRef]

118. Longshaw, V.M.; Baxter, M.; Prewitz, M.; Blatch, G.L. Knockdown of the co-chaperone Hop promotes extranuclear accumulation of Stat3 in mouse embryonic stem cells. *Eur. J. Cell Biol.* 2009, 88, 153–166. [CrossRef]

119. Liu, L.; McBride, K.M.; Reich, N.C. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. *Proc. Natl. Acad. Sci. USA* 2005, 102, 8150–8155. [CrossRef]

120. Echeverría, P.C.; Mazaira, G.; Erlejman, A.; Gomez-Sanchez, C.; Piwien Pilipuk, G.; Galigniana, M.D. Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta. *Mol. Cell Biol.* 2009, 29, 4797–4802. [CrossRef]

121. Adwan, T.S.; Ohm, A.M.; Jones, D.N.; Humphries, M.J.; Reyland, M.E. Regulated binding of importinalpha/alphaB-crystallin: A hybrid solid-state solution-state NMR investigation reveals structural aspects of the heterogeneous oligomer. *J. Mol. Biol.* 2009, 385, 1481–1497. [CrossRef]

122. Langlais, D.; Couture, C.; Balsalobre, A.; Drouin, J. The Stat3/GR interaction code: Predictive value of direct/indirect DNA recruitment for transcription outcome. *Mol. Cell* 2012, 47, 38–49. [CrossRef] [PubMed]

123. Engblom, D.; Kornfeld, J.W.; Schwake, L.; Tronche, F.; Reimann, A.; Beug, H.; Hennighausen, L.; Moriggl, R.; Schütz, G. Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. *Genes Dev.* 2007, 21, 1157–1162. [CrossRef] [PubMed]

124. Wingelhofer, B.; Neubauer, H.A.; Valtent, P.; Han, X.; Constantinescu, S.N.; Gunning, P.T.; Müller, M.; Moriggl, R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. *Leukemia* 2018, 32, 1713–1726. [CrossRef]

125. Ehrnsperger, M.; Gräber, S.; Gaestel, M.; Buchner, J. Binding of non-native protein to Hsp25 during heat shock creates a reservoir of folding intermediates for reactivation. *EMBO J.* 1997, 16, 221–229. [CrossRef]

126. Shashidharamurthy, R.; Koteiche, H.A.; Dong, J.; McHaourab, H.S. Mechanism of chaperone function in regulated binding of importinbeta. *EMBO J.* 2010, 29, 1157–1162. [CrossRef] [PubMed]

127. Choi, S.K.; Kam, H.; Kim, K.Y.; Park, S.I.; Lee, Y.S. Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment? *Cancers (Basel)* 2019, 11, 1195. [CrossRef]

128. Jehle, S.; van Rossum, B.; Stout, J.R.; Noguchi, S.M.; Falber, K.; Rehbein, K.; Oschkinat, H.; Klevit, R.E.; Rajagopal, P. alphaB-crystallin: A hybrid solid-state/solution-state NMR investigation reveals structural aspects of the heterogeneous oligomer. *J. Mol. Biol.* 2009, 385, 1481–1497. [CrossRef]

129. Kostenko, S.; Moens, U. Heat shock protein 27 phosphorylation: Kinases, phosphatases, functions and pathology. *Cell Mol. Life Sci.* 2009, 66, 3289–3307. [CrossRef]
130. Bruey, J.M.; Paul, C.; Fromentin, A.; Hilpert, S.; Arrigo, A.P.; Solary, E.; Garrido, C. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000, 19, 4855–4863. [CrossRef]  
131. Mymrikov, E.V.; Daake, M.; Richter, B.; Haslbeck, M.; Buchner, J. The Chaperone Activity and Substrate Spectrum of Human Small Heat Shock Proteins. J. Biol. Chem. 2017, 292, 672–684. [CrossRef] [PubMed]  
132. Ungelenk, S.; Moayed, F.; Ho, C.T.; Grous, T.; Scharf, A.; Mashaghi, A.; Tans, S.; Mayer, M.P.; Mogk, A.; Bukau, B. Small heat shock proteins sequester misfolding proteins in near-native conformation for cellular protection and efficient refolding. Nat. Commun. 2016, 7, 13673. [CrossRef] [PubMed]  
133. Rocchi, P.; Beraldi, E.; Ettinger, S.; Fazli, L.; Vessella, R.L.; Nelson, C.; Gleave, M. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 2005, 65, 11083–11093. [CrossRef] [PubMed]  
134. Shiota, M.; Bishop, J.L.; Nip, K.M.; Zardan, A.; Takeuchi, A.; Cordonnier, T.; Beraldi, E.; Bazov, J.; Fazli, L.; Chi, K.; et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res. 2013, 73, 3109–3119. [CrossRef]  
135. Shah, M.; Stanek, J.; Handwerger, S. Differential localization of heat shock proteins 90, 70, 60 and 27 in human decidua and placenta during pregnancy. HistoChem. J. 1998, 30, 509–518. [CrossRef]  
136. Matalon, S.T.; Drucker, L.; Fishman, A.; Ornoy, A.; Lishner, M. The Role of heat shock protein 27 in extravillous trophoblast differentiation. J. Cell Biochem. 2008, 103, 719–729. [CrossRef]  
137. Shochet, G.E.; Komemi, O.; Sadeh-Mestechkin, D.; Pomeranz, M.; Fishman, A.; Drucker, L.; Lishner, M.; Matalon, S.T.; Drucker, L.; Fishman, A.; Ornoy, A.; Lishner, M. The Role of heat shock protein-27 (HSP27) regulates STAT3 and eIF4G levels in first trimester human placenta. J. Mol. Histol. 2016, 47, 555–563. [CrossRef]  
138. Suman, P.; Malhotra, S.S.; Gupta, S.K. LIF-STAT signaling and trophoblast biology. JAKSTAT 2013, 2, e25155. [CrossRef]  
139. Gibert, B.; Eckel, B.; Fasquelle, L.; Moulin, M.; Bouhallier, F.; Gonin, V.; Mellier, G.; Simon, S.; Kretz-Remy, C.; Arrigo, A.P.; et al. Knock down of heat shock protein 27 (HspB1) induces degradation of several putative client proteins. PLoS ONE 2012, 7, e29719. [CrossRef]  
140. Shen, L.; Qi, Z.; Zhu, Y.; Song, X.; Xuan, C.; Ben, P.; Lan, L.; Luo, L.; Yin, Z. Phosphorylated heat shock protein 27 promotes lipid clearance in hepatic cells through interacting with STAT3 and activating autophagy. Cell Signal. 2016, 28, 1086–1098. [CrossRef]  
141. Sevin, M.; Kubovčáková, L.; Pernet, N.; Causse, S.; Vitte, F.; Villeval, J.L.; Lacout, C.; Cordonnier, M.; Rodrigues-Lima, F.; Chanteloup, G.; et al. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat. Commun. 2018, 9, 1431. [CrossRef] [PubMed]  
142. Kleppe, M.; Kwaik, M.; Koppikar, P.; Riester, M.; Keller, M.; Bastian, L.; Hricik, T.; Bhagwat, N.; McKenney, A.S.; Papalexi, E.; et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015, 5, 316–331. [CrossRef] [PubMed]  
143. Lee-Yoon, D.; Easton, D.; Murawski, M.; Burd, R.; Subjeck, J.R. Identification of a major subfamily of large hsp70-like proteins through the cloning of the mammalian 110-kDa heat shock protein. J. Biol. Chem. 1995, 270, 15725–15733. [CrossRef] [PubMed]  
144. Oh, H.J.; Easton, D.; Murawski, M.; Kaneko, Y.; Subjeck, J.R. The chaperoning activity of hsp110. Identification of functional domains by use of targeted deletions. J. Biol. Chem. 1999, 274, 15712–15718. [CrossRef] [PubMed]  
145. Mattoo, R.U.; Sharma, S.K.; Priya, S.; Finka, A.; Géroubenoff, P. Hsp110 is a bona fide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates. J. Biol. Chem. 2013, 288, 21399–21411. [CrossRef] [PubMed]  
146. Rampelt, H.; Kirstein-Miles, J.; Nillegoda, N.B.; Chi, K.; Scholz, S.R.; Morimoto, R.I.; Bukau, B. Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J. 2012, 31, 4221–4235. [CrossRef]  
147. Wang, L.; Duke, L.; Zhang, P.S.; Arlinghaus, R.B.; Symmans, W.F.; Sahin, A.; Mendez, R.; Dai, J.L. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 2003, 63, 4724–4730.  
148. Manjili, M.H.; Henderson, R.; Wang, X.Y.; Chen, X.; Li, Y.; Repasky, E.; Kazim, L.; Subjeck, J.R. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res. 2002, 62, 1737–1742.
149. Guo, C.; Subjeck, J.R.; Wang, X.Y. Creation of Recombinant Chaperone Vaccine Using Large Heat Shock Protein for Antigen-Targeted Cancer Immunotherapy. *Methods Mol. Biol. 2018, 1709, 345–357.*

150. Yasuda, K.; Nakai, A.; Hatayama, T.; Nagata, K. Cloning and expression of murine high molecular mass heat shock proteins, HSP105. *J. Biol. Chem. 1995, 270, 29718–29723.*

151. Saito, Y.; Yamagishi, N.; Hatayama, T. Nuclear localization mechanism of Hsp105beta and its possible function in mammalian cells. *J. BioChem. 2009, 145, 185–191.* [CrossRef] [PubMed]

152. Olszak, T.; Neves, J.F.; Dowds, C.M.; Baker, K.; Glickman, J.; Davidson, N.O.; Lin, C.S.; Jobin, C.; Brand, S.; Sotlar, K.; et al. Protective mucosal immunity mediated by epithelial CD1d and IL-10. *Nature 2014, 509, 497–502.* [CrossRef] [PubMed]

153. Yamagishi, N.; Fujii, H.; Saito, Y.; Hatayama, T. Hsp105beta upregulates hsp70 gene expression through signal transducer and activator of transcription-3. *FEBS J. 2009, 276, 5870–5880.* [CrossRef] [PubMed]

154. Yu, N.; Kakunda, M.; Pham, V.; Lill, J.R.; Du, P.; Wongchenko, M.; Yan, Y.; Firestein, R.; Huang, X. HSP105 recruits protein phosphatase 2A to dephosphorylate beta-catenin. *Mol. Cell Biol. 2015, 35, 1390–1400.* [CrossRef]

155. Boudesco, C.; Verhoeyen, E.; Martin, L.; Chassagne-Clement, C.; Salmi, L.; Mhaidly, R.; Pangault, C.; Fest, T.; Ramla, S.; Jardin, F.; et al. HSP110 sustains chronic NF-kappaB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. *Blood 2018, 132, 510–520.* [CrossRef]

156. Berthenet, K.; Bokhari, A.; Lagrange, A.; Marcion, G.; Boudesco, C.; Causse, S.; De Thonel, A.; Svrcek, M.; Goloudina, A.R.; Dumont, S.; et al. HSP110 promotes colorectal cancer growth through STAT3 activation. *Oncogene 2017, 36, 2328–2336.* [CrossRef]

157. Ono, K.; Eguchi, T.; Sogawa, C.; Calderwood, S.K.; Futagawa, J.; Kasai, T.; Seno, M.; Okamoto, K.; Sasaki, A.; Kazuki, K.I. HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. *J. Cell BioChem. 2018, 119, 7350–7362.* [CrossRef]

158. Eguchi, T.; Sogawa, C.; Okusha, Y.; Uchibe, K.; Inumama, R.; Ono, K.; Nakano, K.; Murakami, J.; Itoh, M.; Araki, K.; et al. Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. *PLoS ONE 2018, 13, e0191109.* [CrossRef]

159. Taha, E.A.; Ono, K.; Eguchi, T. Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion. *Int. J. Mol. Sci. 2019, 20, 4588.* [CrossRef]

160. Colgan, S.P.; Pitman, R.S.; Nagaishi, T.; Mizoguchi, A.; Mizoguchi, E.; Mayer, L.F.; Shao, L.; Sartor, R.B.; Subjeck, J.R.; Blumberg, R.S. Intestinal heat shock protein 110 regulates expression of CD1d on intestinal epithelial cells. *J. Clin. Invest. 2003, 112, 745–754.* [CrossRef]

161. Berthenet, K.; Boudesco, C.; Collura, A.; Svrek, M.; Richaud, S.; Hammann, A.; Causse, S.; Youssi, N.; Wanherdrick, K.; Duplomb, L.; et al. Extracellular HSP110 skews macrophage polarization in colorectal cancer. *Oncoimmunology 2016, 5, e1170264.* [CrossRef] [PubMed]

162. Goetz, M.P.; Toft, D.; Reid, J.; Ames, M.; Stensgard, B.; Saftgren, S.; Adjei, A.A.; Sloan, J.; Atherton, P.; Vasile, V.; et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. *J. Clin. Oncol. 2005, 23, 1078–1087.* [CrossRef] [PubMed]

163. Boudesco, C.; Cause, S.; Jego, G.; Garrido, C. Hsp70: A Cancer Target Inside and Outside the Cell. *Methods Mol. Biol. 2018, 1709, 371–396.* [PubMed]

164. Eguchi, T.; Lang, B.J.; Murshid, A.; Prince, T.; Gong, J.; Calderwood, S.K. Regulatory Roles for Hsp70 in Cancer Incidence and Tumor Progression. In *Role of Molecular Chaperones in Structural Folding, Biological Functions, and Drug Interactions of Client Proteins; Galigniana, M.D., Ed.; Bentham Science Publishers: Sharjah, UAE, 2018; Volume 1, pp. 1–22.*

165. Liu, T.; Daniels, C.K.; Cao, S. Comprehensive review on the HSC70 functions, interactions with related molecules and involvement in clinical diseases and therapeutic potential. *Pharmacol. Ther. 2012, 136, 354–374.* [CrossRef] [PubMed]

166. Zhuravleva, A.; Gierasch, L.M. Allosteric signal transmission in the nucleotide-binding domain of 70-kDa heat shock protein (Hsp70) molecular chaperones. *Proc. Natl. Acad. Sci. USA 2011, 108, 6987–6992.* [CrossRef] [PubMed]

167. Chen, S.C.; Guh, J.Y.; Chen, H.C.; Yang, Y.L.; Huang, J.S.; Chuang, L.Y. Advanced glycation end-product-induced mitogenesis is dependent on Janus kinase 2-induced heat shock protein 70 in normal rat kidney interstitial fibroblast cells. *Transl. Res. 2007, 149, 274–281.* [CrossRef] [PubMed]
168. Ghoshal, S.; Rao, I.; Earp, J.C.; Jusko, W.J.; Wetzler, M. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. *Cancer Chemother. Pharmacol.* 2010, 66, 681–689. [CrossRef]

169. Sinn, D.I.; Kim, S.J.; Chu, K.; Jung, K.H.; Lee, S.T.; Song, E.C.; Kim, J.M.; Park, D.K.; Kun Lee, S.; Kim, M.; et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. *NeuroBiol. Dis.* 2007, 26, 464–472. [CrossRef]

170. Uchida, S.; Fujiki, M.; Nagai, Y.; Abe, T.; Kobayashi, H. Geranylgeranylacetone, a noninvasive heat shock protein inducer, induces protein kinase C and leads to neuroprotection against cerebral infarction in rats. *NeuroSci. Lett.* 2006, 396, 220–224. [CrossRef]

171. Guo, F.; Sigua, C.; Bali, P.; George, P.; Fiskus, W.; Scuto, A.; Annavarapu, S.; Mouttaki, A.; Sondarva, G.; Wei, S.; et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. *Blood* 2005, 105, 1246–1255. [CrossRef]

172. Ciocca, D.R.; Arrigo, A.P.; Calderwood, S.K. Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: An update. *Arch. Toxicol.* 2013, 87, 19–48. [CrossRef] [PubMed]

173. Binder, R.J.; Srivastava, P.K. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. *Nat. Immunol.* 2005, 6, 593–599. [CrossRef] [PubMed]

174. Li, Z.; Menoret, A.; Srivastava, P. Roles of heat-shock proteins in antigen presentation and cross-presentation. *Curr. Opin. Immunol.* 2002, 14, 45–51. [CrossRef]

175. Srivastava, P. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. *Annu. Rev. Immunol.* 2002, 20, 395–425. [CrossRef] [PubMed]

176. Srivastava, P. Roles of heat-shock proteins in innate and adaptive immunity. *Nat. Rev. Immunol.* 2002, 2, 185–194. [CrossRef]

177. Elsner, L.; Muppala, V.; Gehrmann, M.; Lozano, J.; Malzahn, D.; Bickeböller, H.; Brunner, E.; Zientkowska, M.; Herrmann, T.; Walter, L.; et al. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. *J. Immunol.* 2007, 179, 5523–5533. [CrossRef]

178. Gross, C.; Hansch, D.; Gastpar, R.; Multhoff, G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. *Biol. Chem.* 2003, 384, 267–279. [CrossRef]

179. Chalmin, F.; Ladoire, S.; Mignot, G.; Vincent, J.; Bruchard, M.; Boireau, W.; Rouleau, A.; Simon, B.; Lanneau, D.; et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. *J. Clin. Investig.* 2010, 120, 457–471.

180. Asea, A.; Kraeft, S.K.; Kurt-Jones, E.A.; Stevenson, M.A.; Chen, L.B.; Finberg, R.W.; Koo, G.C.; Calderwood, S.K. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. *Nat. Med.* 2000, 6, 435–442. [CrossRef]

181. Chen, T.; Guo, J.; Han, C.; Yang, M.; Cao, X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. *J. Immunol.* 2009, 182, 1449–1459. [CrossRef]

182. Starr, R.; Metcalf, D.; Elefanty, A.G.; Brysha, M.; Willson, T.A.; Nicola, N.A.; Hilton, D.J.; Alexander, W.S. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. *Proc. Natl. Acad. Sci. USA* 1995, 92, 14395–14399. [CrossRef] [PubMed]

183. Jiang, M.; Zhang, W.W.; Liu, P.; Yu, W.; Liu, T.; Yu, J. Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment. *Front. Immunol.* 2017, 8, 70. [CrossRef]

184. Babon, J.J.; Kershaw, N.J.; Murphy, J.M.; Varghese, L.N.; Laktyushin, A.; Young, S.N.; Lucet, I.S.; Norton, R.S.; Nicola, N.A. Suppression of cytokine signaling by SOCS3: Characterization of the mode of inhibition and the basis of its specificity. *Immunity* 2012, 36, 239–250. [CrossRef] [PubMed]

185. Fan, Y.X.; Qian, C.; Liu, B.; Wang, C.; Liu, H.; Pan, X.; Teng, P.; Hu, L.; Zhang, G.; Han, Y.; et al. Induction of suppressor of cytokine signaling 3 via HSF1-HSP70-TLR4 axis attenuates neuroinflammation and ameliorates postoperative pain. *Brain Behav. Immun.* 2018, 68, 111–122. [CrossRef] [PubMed]

186. Wang, G.; Xiao, G.; Liu, H.; Chen, G.; Wang, X.; Wen, P.; Li, T.; Wen, J.; Xiao, X. Heat Shock Factor 1 Inhibits the Expression of Suppressor of Cytokine Signaling 3 in Cerulein-Induced Acute Pancreatitis. *Shock* 2018, 50, 465–471. [CrossRef] [PubMed]
187. Stephanou, A.; Isenberg, D.A.; Nakajima, K.; Latchman, D.S. Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. *J. Biol. Chem.* 1999, 274, 1723–1728. [CrossRef]

188. Matozaki, M.; Saito, Y.; Yasutake, R.; Munira, S.; Kaibori, Y.; Yukawa, A.; Tada, M.; Nakayama, Y. Involvement of Stat3 phosphorylation in mild heat shock-induced thermotolerance. *Exp. Cell Res.* 2019, 377, 67–74. [CrossRef]

189. Saito, Y.; Yamagishi, N.; Ishihara, K.; Hatayama, T. Identification of alpha-tubulin as an hsp105alpha-binding protein by the yeast two-hybrid system. *Exp. Cell Res.* 2003, 286, 233–240. [CrossRef]

190. Fritchley, S.J.; Kirby, J.A.; Ali, S. The antagonism of interferon-gamma (IFN-gamma) by heparin: Examination of the blockade of class II MHC antigen and heat shock protein-70 expression. *Clin. Exp. Immunol.* 2000, 120, 247–252. [CrossRef]

191. Chen, X.S.; Zhang, Y.; Wang, J.S.; Li, X.Y.; Cheng, X.K.; Wu, N.H.; Shen, Y.F. Diverse effects of Stat1 on the regulation of hsp90alpha gene under heat shock. *J. Cell BioChem.* 2007, 102, 1059–1066. [CrossRef]

192. Cheng, M.B.; Zhang, Y.; Zhong, X.; Sutter, B.; Cao, C.Y.; Chen, X.S.; Cheng, X.K.; Xiao, L.; Shen, Y.F. Stat1 mediates an auto-regulation of hsp90beta gene in heat shock response. *Cell Signal.* 2010, 22, 1206–1213. [CrossRef] [PubMed]

193. Pak, S.H.; Joung, Y.H.; Park, J.H.; Lim, E.J.; Darvin, P.; Na, Y.M.; Hong, D.Y.; Lee, B.; Hwang, T.S.; Park, T.; et al. Hypoxia upregulates Hsp90x expression via STAT5b in cancer cells. *Int. J. Oncol.* 2012, 41, 161–168. [PubMed]

194. Song, H.; Ethier, S.P.; Dziubinski, M.L.; Lin, J. Stat3 modulates heat shock 27kDa protein expression in breast epithelial cells. *Biochem. Biophys. Res. Commun.* 2004, 314, 143–150. [CrossRef] [PubMed]

195. Xu, N.W.; Chen, Y.; Liu, W.; Chen, Y.J.; Fan, Z.M.; Liu, M.; Li, L.J. Inhibition of JAK2/STAT3 Signaling Pathway Suppresses Proliferation of Burkitt’s Lymphoma Raji Cells via Cell Cycle Progression, Apoptosis, and Oxidative Stress by Modulating HSP70. *Med. Sci. Monit.* 2018, 24, 6255–6263. [CrossRef]

196. Krawczyk, Z.; Gogler-Pigłowska, A.; Sojka, D.R.; Scieginska, D. The Role of Heat Shock Proteins in Cisplatin Resistance. *Anticancer Agents Med. Chem.* 2018, 18, 2093–2109. [CrossRef]

197. Chatterjee, S.; Burns, T.F. Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach. *Int. J. Mol. Sci.* 2017, 18, 1978. [CrossRef]

198. Saini, J.; Sharma, P.K. Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer. *Curr. Drug Targets* 2018, 19, 1478–1490. [CrossRef]